KMTS Kestra Medical Technologies, Ltd.
Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease through connected monitoring, therapeutic intervention, and data-driven clinical insights. The company also develops and commercializes Cardiac Recovery System platform, an integrated cardiac recovery ecosystem designed to support patients at elevated risk of sudden cardiac arrest (SCA) during vulnerable periods of recovery. Its platform provides ASSURE Wearable Cardioverter Defibrillator (WCD), which continuously monitors patient heart rhythms and automatically delivers defibrillation therapy when life-threatening ventricular arrhythmias are detected; digital patient engagement and clinical workflow solutions designed to improve patient adherence, support care coordination, and provide actionable clinical insights throughout the recovery process; and integrated platform generates continuous cardiac rhythm data and clinically actionable insights. Kestra Medical Technologies, Ltd. was founded in 2014 and is based in Kirkland, Washington.…
Industry Peers
Medical Instruments & SuppliesKey Statistics
About Kestra Medical Technologies (NASDAQ: KMTS)
›
Kestra Medical Technologies (NASDAQ: KMTS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 443 employees.
The shares were at 26.63 USD on 19 November 2026, up 3.8% over 52 weeks. Its 52-week range is 17.34 USD to 31.98 USD: the price is 16.7% below the high and 53.6% above the low.
Its market capitalisation is 1.59B USD.
Kestra Medical Technologies reports return on equity of -50.7%, an operating margin of -134.5% and revenue up 59.9% year over year.
It holds more cash than debt, a net cash position of 122.47M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 8 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 31.13 USD is 16.9% above the current price. The next earnings report is expected on 14 December 2026.